![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
CASE REPORTS
Minerva Pneumologica 2014 March;53(1):43-5
Copyright © 2014 EDIZIONI MINERVA MEDICA
language: English
Hepatotoxicity due to montelukast: a case-based review of literature
Sargin G. 1, Coskun A. 2, Yavasoglu I. 3, Yasa M. H. 2
1 Department of Internal Medicine Adnan Menderes University Medical Faculty Aydin, Turkey; 2 Division of Gastroenterology Adnan Menderes University Medical Faculty Aydin, Turkey; 3 Division of Hematology Adnan Menderes University Medical Faculty Aydın, Turkey
Montelukast is a selective antagonist of cysteinyl leukotriene receptors. Drug-induced hepatotoxicity and abnormal levels of serum aminotransferases may be detected in patients without any clinical symptoms. In literature, several side effects about montelukast have been reported with clinical sings such as jaundice etc. with elevated bilirubin levels. Here, we report 60-year-old female patient who had a medical history about montelukast receiving and elevated serum aminotransferases without any clinical sings.